Literature DB >> 19418840

[Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study].

Eduardo Martínez Agulló1, José L Ruiz Cerdá, Luis Gómez Pérez, Miguel Ramírez Backhaus, Francisco Delgado Oliva, Pablo Rebollo, Diego González-Segura Alsina, Daniel Arumi.   

Abstract

BACKGROUND: Despite the growing interest on Urinary Incontinence (UI) in our country, nocturnal enuresis and Overactive Bladder (OAB), there are no epidemiologic studies on the prevalence of these health problems in the different affected groups of the general population. PATIENTS AND METHODS: This is an epidemiologic, observational, multicentre and national study. Data were collected by means of personal interviews in 5 representative areas from Spain and in 4 groups of population: 1) working women (25- 64-years-old); 2) working men (50- 64-years-old); 3) children attending primary school (6- 11-years-old); and 4) elderly institutionalized subjects (over 65-years-old) with no mental impairment. The Interview addressed to adult population included two parts: 1) socio-demographic variables and clinical history; and 2) data about OAB and UI symptoms. The Interview addressed to children included socio-demographic variables and questions about liquid intake and urine control.
RESULTS: Percentage of answer to interview in the different groups varied between 79.7% and 98%. Prevalence of isolate OAB and UI in working women were 2.69% and 4.01% respectively; in men were 3.55% and 0.56%; in elderly were 9.14% and 15.16%. In total, 9.94% (95%CI = 8.9-11.04) of the women under study suffer one or both health problems; this percentage was 5.14% (95% CI= 3.89-6.63) in men and 53.71% (95% CI= 50.56-56.85) in elderly. Prevalence of nocturnal enuresis in children was 7.82% (95% CI= 6.62-9.17).
CONCLUSIONS: Prevalence of OAB and/or UI in Spain is near 10% of women between 25 and 64 years, is around 5% in men between 50 and 64 years and it is over 50% in persons over 65 years; prevalence of nocturnal enuresis in children between 6 and 11 years is around 8%.

Entities:  

Mesh:

Year:  2009        PMID: 19418840     DOI: 10.1016/s0210-4806(09)74117-8

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  15 in total

1.  Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Authors:  Salvador Arlandis; Miguel A Ruiz; Carlos Errando; Felipe Villacampa; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

2.  Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.

Authors:  Antoni Sicras-Mainar; Ruth Navarro-Artieda; Amador Ruiz-Torrejón; Marc Sáez-Zafra; Gabriel Coll-de Tuero
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

3.  Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluación del Control de la Vejiga (CACV).

Authors:  Félix Lugo Salcedo; Rafael Sánchez Borrego
Journal:  Int Urogynecol J       Date:  2013-02-27       Impact factor: 2.894

4.  Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  Int Urogynecol J       Date:  2013-11-06       Impact factor: 2.894

5.  Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Authors:  Salvador Arlandis-Guzman; Carlos Errando-Smet; Jeffrey Trocio; Daniel Arumi; Javier Rejas
Journal:  BMC Urol       Date:  2011-05-20       Impact factor: 2.264

6.  Evaluation of a behavioral treatment for female urinary incontinence.

Authors:  Marta Santacreu; Rocío Fernández-Ballesteros
Journal:  Clin Interv Aging       Date:  2011-06-08       Impact factor: 4.458

7.  Remeex® System Effectiveness in Male Patients with Stress Urinary Incontinence.

Authors:  Gerardo-Alfonso Márquez-Sánchez; Bárbara-Yolanda Padilla-Fernández; Miguel Perán-Teruel; Pedro Navalón-Verdejo; Sebastián Valverde-Martínez; Magaly-Teresa Márquez-Sánchez; Javier Flores-Fraile; María-Fernanda Lorenzo-Gómez
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

8.  Observational Study on the Prevalence of Urinary Incontinence in Female Athletes.

Authors:  Jorge Velázquez-Saornil; Encarnación Méndez-Sánchez; Sonia Gómez-Sánchez; Zacarías Sánchez-Milá; Ester Cortés-Llorente; Ana Martín-Jiménez; Elena Sánchez-Jiménez; Angélica Campón-Chekroun
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

9.  Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study.

Authors:  David Castro-Diaz; Pilar Miranda; Francisco Sanchez-Ballester; Isabel Lizarraga; Daniel Arumí; Javier Rejas
Journal:  BMC Urol       Date:  2012-07-26       Impact factor: 2.264

10.  Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  BMC Urol       Date:  2013-10-21       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.